Three companies unveiled share-repurchase authorizations totaling $634.3M during the week of August 17–23, 2026, and every one of them is a first-time repurchaser on record. The set is small in count but uneven in scale: Hni Corp (HNI $48.23 -2.88%) led with a $284.3M program announced August 17, James Hardie Industries plc (JHX $29.86 -1.74%) followed with a $250M program on August 20, and United States Antimony Corp (UAMY $5.44 +4.62%) closed the week with a $100M program on August 19. HNI's authorization alone accounts for 44.8% of the week's total, and at 1.1 times the size of the runner-up, the set is only mildly top-heavy rather than dominated by a single name.
HNI: a sizable authorization, a thin cash cushion
HNI's $284.3M ceiling is the first repurchase program on the company's repurchase history, making it a debut authorization. Against an $3.55B market cap, the program is 8.0% of equity value — material for a first-time buyer, but framed by a cash position that does most of the heavy lifting in reverse. The company's balance sheet and cash flows show $105M in cash and equivalents, a 0.4x coverage of the authorization. On the fiscal year ended 2026-01-03, HNI generated $208.5M of free cash flow, putting the program at 1.4 years of free cash flow to fund and roughly 1.0 year of operating cash flow ($276.3M).
In plain terms, HNI can fund this authorization from a little over a year of free cash flow, but not from cash on hand alone. The price history provides context: shares closed at $49.23, up 13.3% over the trailing year and only 6.3% off the trailing-year high, so the authorization lands near the cycle top rather than in a drawdown. HNI's industry, Furnishings, Fixtures & Appliances, has seen one other program in the trailing 90 days (peer LZB), so HNI is the second authorization in its peer cluster this quarter.
James Hardie: largest market cap, easiest-to-fund program
James Hardie Industries plc is also a first-time repurchaser, according to its repurchase history, and its $250M program is the most comfortably funded of the three. Against an $17.67B market cap, the authorization is just 1.4% of equity value, modest in relative terms, but the financials tell the more interesting story. Cash and equivalents of $289.9M cover the program 1.2x, meaning cash on hand is already enough to execute the authorization outright.
The data behind this piece
Explore the primary data Equibles carries for HNI:
On the fiscal year ended 2026-03-31, James Hardie produced $205.9M of free cash flow and $589.8M of operating cash flow, putting the program at 1.2 years of free cash flow and 0.4 years of operating cash flow to fund. The backdrop reinforces the picture: shares closed at $30.43, up 53.8% over the trailing year and just 2.1% off the trailing-year high, so management is authorizing repurchases at almost exactly the cycle peak. Within Building Materials, James Hardie is the only program in the trailing 90 days, so there is no peer cluster to read against.
United States Antimony: the program that strains capacity
United States Antimony Corp rounds out the week with a $100M program that is, on paper, the most stretched. Its repurchase history shows no prior program, making this another first-time authorization. The financials are the constraint: cash and equivalents of $30.5M cover the program 0.3x, and on the fiscal year ended 2025-12-31 the company posted negative cash flow, with operating cash flow of -$9.7M and free cash flow of -$37.5M.
Because cash flow is negative, the years-to-fund figures are not meaningful and the authorization cannot be funded from internally generated cash under current operating conditions. The program is 12.2% of the $821.7M market cap, a meaningful slice of equity value. The price history frames the announcement sharply: shares closed at $5.49, up 20.9% over the trailing year but 68.6% below the trailing-year high, so unlike the other two authorizations this one arrives deep in a drawdown. United States Antimony stands alone in Other Industrial Metals & Mining, with no other program in that industry over the trailing 90 days.
What the week adds up to
The week's set is defined less by its aggregate than by what it is not: there is no repeat buyer, no prior program to measure against, and no second authorization in either JHX's or UAMY's industry. HNI's $284.3M is 1.1 times the runner-up, so the set is top-heavy only mildly, and the strongest supported reading from the disclosed evidence is the contrast in funding posture. James Hardie can execute from cash, HNI can fund from roughly 1.4 years of free cash flow, and United States Antimony's authorization is, on the stated numbers, the program least able to be funded from current operations.
Method note: Figures come from SEC filings and market data, cover programs announced in the stated window, and include USD programs only.